Identification of Airway-Mucosal Type-2 inflammation by Clinical Biomarkers in Asthma

A panel of clinically-accessible biomarkers (FENO, blood eosinophils, serum CCL17 and CCL26) identified asthma patients with an airway 'Type-2-high' or 'Type-2-low' phenotype based on expression of airway-mucosal-CCL26, periostin, or an IL-13 multigene signature. This combination may prove useful in selecting patients for novel therapies targeting Type-2 inflammation.

http://ift.tt/2jICCVQ